Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation p…
$7.42-0.27%
报价 2026-11-13
市值
$271.8M
EV
$209.2M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -14.2%
$5.06$8.65
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Medical - Devices| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PROFProfound Medical Corp. | $271.8M | -0.3% | – | 71.7% | – | – | – | |
| VMDViemed Healthcare, Inc. | $347.5M | +0.7% | +16.8% | 57% | 23.4x | 6.9x | 16.3x | GARP |
| TMCITreace Medical Concepts, Inc. | $345.5M | -1.3% | -1.9% | 79.6% | – | – | – | |
| SSIISS Innovations International, Inc. | $332.8M | +25.8% | +13.8% | 47% | – | – | – | |
| OFIXOrthofix Medical Inc. | $292.2M | +3.3% | +3.1% | 69.6% | – | 5.7x | – | |
| LABStandard BioTools Inc. | $279.3M | +8.6% | +2.7% | 48.3% | – | – | – | |
| CLPTClearPoint Neuro, Inc. | $271.8M | -0.1% | +45.1% | 62.6% | – | – | – | |
| NPCENeuroPace, Inc. | $260.5M | -37.1% | +5.5% | 77.2% | – | – | – | |
| RXSTRxSight, Inc. | $223.1M | -1.1% | -1.7% | 76.6% | – | – | 12.0x | |
| 同行中位数 | – | – | +4.3% | 66.1% | 23.4x | 6.3x | 14.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。